8-K: InspireMD Reports 22% Revenue Increase in Q1 2024, Advances Clinical Trials

InspireMD announced a 22% year-over-year increase in CGuard revenue for the first quarter of 2024, alongside progress in clinical trials and key appointments.

Summary

• InspireMD reported a 22% increase in CGuard revenue, reaching $1.51 million in the first quarter of 2024, compared to $1.239 million in the same period last year.
• The company sold 2,553 CGuard EPS stent systems in Q1 2024, a 25.6% increase from 2,033 in Q1 2023.
• Gross profit decreased by 21.6% to $292,000 due to higher training costs, resulting in a gross margin of 19.4%.
• Total operating expenses increased by 62.1% to $7.706 million, primarily due to higher share-based compensation.
• The net loss for the quarter was $7.032 million, or $0.21 per share, compared to a net loss of $4.256 million, or $0.53 per share, in Q1 2023.
• Cash, cash equivalents, and marketable securities totaled $34.0 million as of March 31, 2024, down from $39.0 million at the end of 2023.
• The company announced that one-year outcomes from the C-GUARDIANS IDE clinical trial will be presented at LINC 2024 in May.
• The presentation of one-year results could trigger the first of four $17.9 million financing tranches from a private placement announced in May 2023.
• InspireMD named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the CGUARDIANS II clinical trial.
• The company also announced the appointment of Pete Ligotti as Executive Vice President and General Manager of North America.

Sentiment

Score: 6

Explanation: The document presents mixed results. While there is strong revenue growth and clinical trial progress, the increased net loss and decreased gross profit raise concerns. The potential for a capital raise is also a factor.

Positives

• The company experienced a significant 22% increase in CGuard revenue year-over-year.
• Stent sales volume increased by 25.6% year-over-year, indicating strong market demand.
• The presentation of one-year clinical trial results at LINC 2024 is a positive step towards regulatory approval.
• The company has reached a milestone of over 50,000 CGuard EPS stents sold.
• The 30-day clinical trial results showed a low major adverse event rate of 0.95% with CGuard.
• The company has secured key investigators for the CGUARDIANS II clinical trial.
• The company has successfully recertified its CE Mark under the new European MDR framework.
• Financial income increased significantly due to higher interest income.

Negatives

• Gross profit decreased by 21.6% due to higher training costs.
• Gross margin decreased to 19.4% from 30.1% in the same quarter last year.
• Total operating expenses increased by 62.1%, primarily due to higher share-based compensation.
• The net loss for the quarter increased to $7.032 million, compared to $4.256 million in Q1 2023.
• Cash, cash equivalents, and marketable securities decreased from $39.0 million to $34.0 million during the quarter.

Risks

• The company has a history of recurring losses and negative cash flows.
• There is uncertainty regarding the adequacy of the company's liquidity to pursue its business objectives.
• The company may need to raise additional capital, which could be costly or difficult to obtain and dilute existing shareholders.
• There are risks associated with securing and maintaining regulatory approvals for the sale of products.
• Negative clinical trial results or lengthy product delays in key markets could impact the company.
• The company faces intense competition in the industry.
• The company is dependent on a single manufacturing facility.
• There are risks associated with conducting business in multiple foreign jurisdictions, including currency fluctuations and political instability.

Future Outlook

The company anticipates a potential FDA Premarket Approval (PMA) application later this year and potential approval in the first half of 2025. They are also focused on advancing their clinical trials and new product pipeline, preparing for a launch of their carotid platforms in the U.S.

Management Comments

• Our first quarter results reflect continued momentum and share gains in our served CE Mark territories, including total revenue of $1.51 million that increased 22.0% year-over-year.
• We sold more than 2,500 stents during the quarter, up 25.6% year-over-year and bringing our real-world experience with the CGuard EPS stent platform to over 50,000 stents sold to date, a noteworthy milestone for our company.
• We remain acutely focused on advancing our ongoing C-GUARDIANS PMA clinical trial through to completion for U.S. market approval.
• These are best-in-class results from any carotid pivotal trial conducted to date and form the foundation of our stent first strategy.
• I am very pleased with our progress, including building our core business as well as advancing our clinical trials and new product pipeline, anticipating and preparing for a launch of our best-in-class carotid platforms in the U.S. in 2025.

Industry Context

The announcement highlights InspireMD's efforts to establish its CGuard EPS as a leading solution for carotid artery disease, a market with significant unmet needs. The company's focus on clinical trials and regulatory approvals aligns with the industry's emphasis on evidence-based medicine and patient safety. The appointment of key investigators and the expansion of the management team indicate a strategic push to gain market share and prepare for commercialization in the US.

Comparison to Industry Standards

• The 0.95% major adverse event rate (DSMI) reported in the 30-day results of the C-GUARDIANS trial is notably low compared to historical rates for carotid endarterectomy (CEA), which can range from 2% to 6% depending on patient risk factors.
• Competitors in the carotid stenting market include companies like Abbott, Medtronic, and Boston Scientific, which have established products and significant market presence. InspireMD's focus on its MicroNet technology and the CGuard EPS aims to differentiate it from these competitors.
• The company's strategy of a 'stent first' approach is a direct challenge to the traditional preference for CEA in high-risk patients, and the clinical trial results are crucial for demonstrating the safety and efficacy of their approach.
• The 22% revenue growth and 25.6% increase in stent sales indicate a strong market uptake in CE Mark territories, but the company needs to demonstrate similar success in the US market to compete effectively with established players.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased gross profit, but encouraged by the revenue growth and clinical trial progress.
• Employees may benefit from the company's growth and expansion, but may also be impacted by the cost-cutting measures.
• Customers may benefit from the company's innovative products and services.
• Suppliers may benefit from the company's increased sales and production.
• Creditors may be concerned about the company's increased net loss and decreased cash position.

Next Steps

• Presentation of one-year outcomes from the C-GUARDIANS IDE clinical trial at LINC 2024 in May.
• Potential filing of a Premarket Approval (PMA) application with the FDA later this year.
• Potential approval in the first half of 2025.
• Advancement of the CGUARDIANS II clinical trial.
• Continued focus on building the core business and advancing the new product pipeline.

Key Dates

Keywords

CGuard EPS, Carotid Artery Disease, Stent, Clinical Trial, Revenue, Medical Device, Regulatory Approval, Stroke Prevention, PMA, CE Mark